OBJECTIVE	We assessed 48-week changes in sCD14 and other inflammatory biomarkers in virologically suppressed , HIV-infected women switching to raltegravir ( RAL ) from a protease inhibitor ( PI ) or nonnucleoside reverse transcriptase inhibitor ( NNRTI ) .\